Stock of the Day

August 9, 2019

Solid Biosciences (SLDB)

$5.74
+$0.27 (+4.9%)
Market Cap: $585.99M

About Solid Biosciences

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Today's Trend

Solid Biosciences Inc. (NASDAQ: SLDB) shares have edged higher as HC Wainwright delivered a broadly favorable update to its earnings outlook and reiterated a Buy rating with a $25 price target.

  • HC Wainwright raised its EPS forecasts for 2026 and 2027, including FY2026 to a loss of $1.63 per share from $1.72 previously and FY2027 to a loss of $1.59 from $1.72. The firm also improved estimates for each quarter from Q3 2026 through Q4 2027, suggesting expectations for smaller losses. HC Wainwright Solid Biosciences estimates
  • The analyst raised its FY2028 EPS forecast to a loss of $1.23 per share from $1.33 and FY2029 EPS to $0.27 from $0.26. The estimates continue to project a transition to profitability by FY2029, with earnings reaching $1.80 per share in FY2030. Solid Biosciences long-term earnings estimates
  • HC Wainwright maintained its $25 target, implying substantial potential upside from Solid Biosciences’ recent trading level. However, the company remains unprofitable, and the current-year consensus still calls for a loss of approximately $1.76 per share. Solid Biosciences analyst rating and target
  • HC Wainwright modestly reduced its FY2030 EPS estimate to $1.80 from $1.88. Although the company is still expected to be profitable, the cut slightly tempers the longer-term earnings outlook. Solid Biosciences FY2030 estimate
← Previous Stock of the DayNext Stock of the Day →

Recent News